This programme provides funding for Aclasta infusions for eligible patients
The infusion is to be provided in the community by the patient’s general practice.
Your Pinnacle Services Contract applies to this service. By claiming for this service, you have indicated that you have read and agreed to the business rules set out here.
This is NOT a clinical guideline.
All Pinnacle practices in Te Whatu Ora Lakes region can claim for this service.
Patients who are Māori, Pacific, a CSC holder or are Quintile 5 and who meet the special authority criteria (SA1780) for the administration of zoledronic acid.
Patients domiciled in Te Whatu Ora Lakes area.
Please make your claim via Primary Options, select Aclasta Infusion and then attach the appropriate invoice(s).
Aclasta: $150 (including GST)
Please be aware the claim is all inclusive of the GP consult, the administration of the infusion, observation time and consumables.
This service does not include the cost of the medication on special authority, this is the responsibility of the patient to purchase.
The dosing and frequency of administration varies, in accordance with the indication for use. Each administration will require a new claim.
Practices are required to provide sufficiently detailed consultation notes to determine appropriate use of funding.
It has been recommended that in addition to a good assessment and history, the eligibility criteria are clearly stated in the clinical notes.
A patient co-payment cannot be charged.
This service does not include the cost of the medication on special authority, this is the responsibility of the patient to purchase.
The service is funded by Te Whatu Ora.
Primary options team, Pinnacle Midlands Health Network
infoprimaryoptions@pinnacle.health.nz
027 687 7312
An occasional series illustrating the value of using PowerBI to explore your own data. This issue focuses on 'off label' use of melatonin.
Read moreThe Special Authority criteria for Concerta and Ritalin LA has been amended. This removes the criterion allowing treatment initiation on to Concerta or Ritalin LA if unable to access Teva-ER due to supply issues. This is because all strengths of Methylphenidate ER - Teva, are available again. However supply of Concerta is now constrained.
Read moreDr Jo Scott-Jones and Dr Dave Maplesden discuss assessing capacity (in activating enduring power of attorney), HPV screening, changes to opioid prescribing and more.